November 29, 2014     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
News Sectors
Health & Med
IT & Internet
Real Estate
Science & Research
Annual Reports
News Alerts
News Search
Photo Gallery
Client Login
Japan Corporate News Network
About JCN
Privacy Policy
Terms of Use

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. 

Company Headquarters 4-6-10 Koishikawa, Bunkyo-ku,Tokyo 112-8088, JAPAN 
Company Telephone +81-3-3817-3724 
Company Stock Code - TSE
 CompanyStock Price - TSE   
Company Stock Code - U.S.
 CompanyStock Price - U.S.
Company CEO Haruo Naito 
Company Sector Alternative Energy 
Company Industries Pharmaceutical
Company Established 1941 
Company Listed 1961 
Company Homepage
Company Annual Report
Company CSR Report

Headline News for Eisai  

No records were found in the Headlines


Press Releases for Eisai  

Eisai Opens New Packaging Facility at Hatfield Production Plant in U.K. (Nov 28, 2014)

Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil (Nov 26, 2014)

Eisai Launches Antiepileptic Drug Fycompa in Hong Kong (Nov 21, 2014)

Eisai's Ranking Significantly Increases in the Access to Medicine Index 2014 (Nov 17, 2014)

Lorcaserin Meets Primary Endpoint and Confirms Proof-Of-Concept as Potential Aid for Smoking Cessation in Investigational Phase II Clinical Study (Nov 4, 2014)

Eisai Announces Top-Line Results of Investigational Study on Coadministration of Lorcaserin and Phentermine (Oct 29, 2014)

U.S. FDA Accepts sNDA For Antiepileptic Agent Fycompa as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures (Oct 21, 2014)

U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib (Oct 15, 2014)

U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome (Oct 15, 2014)

U.S. FDA Approves Antiemetic Agent Akynzeo For Prevention Of Chemotherapy-Induced Nausea and Vomiting (CINV) (Oct 14, 2014)

Eisai Launches Anti-Cancer Agent Halaven in Australia (Oct 1, 2014)

Phase III Trial of Aricept in Patients with Severe Alzheimer's Disease in China Meets Primary Endpoint (Sep 30, 2014)

Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies (Sep 19, 2014)

Plasmacluster Ion Technology Reduced Airway Inflammation in Pediatric Patients with Mild to Moderate Atopic Asthma (Sep 18, 2014)

Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin) and Lenvatinib at 39th ESMO Congress (Sep 17, 2014)

Eisai Enters Two Joint Research Agreements to Develop New Antimalarial Medicines (Sep 16, 2014)

Eisai and Kyorin Enter Into Agreement Concerning Compound Library Use for the Development of New Antibacterial Agents (Sep 11, 2014)

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)

Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)

Eisai Supports Earthquake Relief Efforts in Yunnan, China (Aug 7, 2014)

Previous... More...



• Register for News Alerts about Eisai here

• Back to Previous Page

• View more Company Profile Listings

Photo News

Suprema Wins All-Over-IP Award as Best Product
More >> 
Annual Reports

  More >>    
CSR Reports

  More >> 

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)